News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Epic Sciences Appoints Jason Adams As Vice President Of Business Development



5/28/2014 7:02:06 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, May 28, 2014 /PRNewswire/ -- Epic Sciences announced today the appointment of Jason Adams as vice president of business development. Mr. Adams has more than 15 years of experience in biotech and diagnostic business development. Mr. Adams has specialized in negotiating and structuring complex revenue generating business development partnerships, in-licensing of high value technologies, and conducting due diligence for potential acquisition opportunities. Prior to joining Epic Sciences, Mr. Adams served as asenior member of the companion diagnostics business development group at Ventana Medical Systems, Inc., a member of the Roche Group.

Epic Sciences announced today the appointment of Jason Adams as vice president of business development to advance Epics leading circulating tumor cell (CTC) technology as a rapid and non-invasive platform for on-label, marketed companion diagnostics. Mr. Adams has specialized in negotiating and structuring complex revenue generating business development partnerships, in-licensing of high value technologies, and conducting due diligence for potential acquisition opportunities. Prior to joining Epic Sciences, Mr. Adams served as a senior member of the companion diagnostics business development group at Ventana Medical Systems, Inc., a member of the Roche Group.

"Jason has a unique ability to coalesce important transactions for on-label, marketed companion diagnostics that deliver significant value for partners," said Murali Prahalad, Ph.D., president and CEO, Epic Sciences. "At Epic, Jason will apply his technical depth, customer relationships and business acumen to drive Epic's strategic goals of advancing our leading CTC technology with pharmaceutical partners. We believe Epic's CTC technology provides the most essential information to match patients to clinical trials or to approved therapeutics and to monitor for drug resistance."

"I have seen the positive impact that companion diagnostics can have to enable faster and more efficient clinical trials by informing patient selection and providing therapeutic monitoring," said Mr. Adams, vice president of business development, Epic Sciences. "Epic's 'no cell left behind' approach is delivering to pharma a robust and reliable identification and characterization of circulating tumor cells in blood, including, in-depth, single-cell protein expression and genomic analysis. I look forward to playing a transformative role in working with Epic and its partners to advance important new diagnostic tools that work with new, targeted therapies to better manage cancer and improve clinical benefit for patients."

Mr. Adams has spent the last seven years at Ventana Medical Systems, where he has held roles with increasing responsibility. He was most recently a senior member of the companion diagnostic business development group, where he negotiated and managed alliances and partnerships with global pharmaceutical companies, including, Pfizer, Seattle Genetics and Millennium, and developed high-value companion diagnostics. He also held additional roles, including as a leader of marketing, strategic planning, corporate development and scientific teams. Prior to Ventana, he was a business development manager and scientist at SGX Pharmaceuticals, an analyst at Ligand Pharmaceuticals and a research associate at Invitrogen (now Life Technologies, a brand of Thermo Fisher Scientific). He received his MBA in finance and technology management from UCLA Anderson School of Management and his B.S. in molecular and cellular biology from the University of Arizona.

About Epic Sciences

Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic's mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient's journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Our technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic's goal is to commercialize our technology to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians real-time information to guide treatment choices.

Further information is available on the Company's website, www.epicsciences.com. Stay in touch on Twitter @EpicSciences or on Facebook.com/EpicSciences.

Photo - http://photos.prnewswire.com/prnh/20140520/89733

SOURCE Epic Sciences



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES